The initial public offer of Standard Glass Lining Technology Ltd got fully subscribed within minutes of opening for share sale on Monday and finally ended the day with 13.32 times subscription.
The public issue received bids for 27,75,00,862 shares against 2,08,29,567 shares on offer, translating into 13.32 times subscription, as per NSE data.
The quota for non-institutional investors garnered 25.42 times subscription while Retail Individual Investors (RIIs) part fetched 14.46 times subscription. Qualified Institutional Buyers (QIBs) portion received 1.82 times subscription.
Standard Glass Lining Technology on Friday said it has mobilised Rs 123 crore from anchor investors.
The issue, with a price band of Rs 133-140 per share, will conclude on January 8.
The Rs 410.05 crore public issue is a combination of fresh issuance of equity shares worth Rs 210 crore and an Offer For Sale (OFS) of up to 1.43 crore shares by promoters and other selling shareholders, according to the Red Herring Prospectus (RHP).
S2 Engineering Services, Kandula Ramakrishna, Kandula Krishna Veni, Nageswara Rao Kandula, Standard Holdings, Katragadda Venkata Ramani, and Venkata Siva Prasad Katragadda are among shareholders selling shares through the OFS route.
Proceeds from the fresh issue to the extent of Rs 130 crore will be used by the company for debt repayment and Rs 30 crore for investment in a wholly-owned subsidiary S2 Engineering Industry.
Funds worth Rs 20 crore will also be utilised by the company towards inorganic growth through strategic investments or acquisitions, Rs 10 crore for the purchase of machinery and equipment and a portion will also be used for general corporate purposes.
Standard Glass Lining Technology offers comprehensive solutions that encompass design, engineering, manufacturing, assembly, installation, and commissioning and establishing standard operating procedures for pharmaceutical and chemical manufacturers on a turnkey basis.
Some of its pharma clients, include Aurobindo Pharma, Cadila Pharmaceutical, Granules India Ltd, Macleods Pharmaceuticals, Piramal Pharma, and Suven Pharmaceuticals.
IIFL Capital Services Ltd (formerly known as IIFL Securities Ltd) and Motilal Oswal Investment Advisors Ltd are the book-running lead managers, while KFin Technologies is the registrar for the issue.
The shares will be listed on the BSE and the National Stock Exchange (NSE).
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)